Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Deutsches Krebsforschungszentrum

Bayer Aktiengesellschaft

Iomx Therapeutics Ag

Schirrmacher, Dr., Volker

Philipp Beckhove

Michael Boutros

Marco Breinig

Volker Schirrmacher

Nisit Khandelwal

Mark Trautwein

Jörg Willuda

Rienk Offringa

Peter Sennhenn

Sebastian Meier-ewert

Philippe Fournier

Maximilian Aigner

Nora Sommerfeldt

Valentina Volpin

Hans-Henning Böhm

Ayse Nur Menevse

Antonio Sorrentino

Tillmann Michels

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.

Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.

Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies

The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.

Cytotoxic T cell response modifiers

The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.

Multi-modal cancer therapy using viral hitch-hiking

Disclosed is a vaccine against diseases, particularly tumor diseases, being associated with an enhanced heparanase expression and/or activity, wherein the vaccine contains a heparanase peptide, which binds to a HLA molecule.

Heparanase-derived peptides for vaccination of tumor patients

Growing community of inventors

Heidelberg, Germany

Philipp Beckhove